RBC Life Sciences, Inc.
RBCL · OTC
9/30/2017 | 6/30/2017 | 3/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.03 | 0.00 |
| FCF Yield | -22.68% | 29.43% | -106.90% | 4.60% |
| EV / EBITDA | 1.02 | 0.96 | -1.75 | 6.42 |
| Quality | ||||
| ROIC | -5.13% | -1.60% | 0.62% | -3.57% |
| Gross Margin | 51.79% | 56.45% | 53.36% | 49.49% |
| Cash Conversion Ratio | 0.23 | -1.67 | -11.26 | -0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.72% | -0.25% | -1.99% | -3.04% |
| Free Cash Flow Growth | -150.91% | 130.84% | -2,036.65% | -94.51% |
| Safety | ||||
| Net Debt / EBITDA | 2.54 | 6.51 | -11.72 | 11.71 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.41 | 0.42 | 0.59 | 0.88 |
| Cash Conversion Cycle | 111.79 | 122.05 | 110.85 | 76.92 |